Abstract 359P
Background
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) have shown promising efficacy in clinical trials for resected EGFR mutant NSCLC. However, it is still unclear which type of adjuvant regimens can provide best survival benefit among multiple therapeutic strategies. Herein, we performed a network meta-analysis to comprehensively compare the efficacy and safety of adjuvant treatments for resected EGFR mutant NSCLC.
Methods
Studies comparing two or more adjuvant treatments for resected EGFR mutant NSCLC were included. Study outcomes were DFS and OS with hazard ratio and adverse events with odds ratio. The primary endpoint was DFS. Registration number: PROSPERO (CRD42020184514).
Results
10 eligible trials involved 2707 patients and 6 treatments: 3 EGFR-TKIs (osimertinib, erlotinib, gefitinib), TKI following chemotherapy (CT+TKI), chemotherapy alone and placebo. Osimertinib showed the most favorable DFS, with significant superiority versus erlotinib (HR 0.4, 95% CI 0.24-0.66), gefitinib (0.42, 0.26-0.67), chemotherapy (0.23, 0.15-0.33) and placebo (0.17, 0.12- 0.24), but with no significant improvement versus CT +TKI (0.86, 0.42-1.74). CT +TKI provided the best OS benefit across assessable treatments (versus placebo, HR, 0.6 [0.11, 3.34]). OS data form osimertinib was not yet mature. Osimertinib had the fewest toxicity, whereas CT +TKI or chemotherapy alone caused most toxic effects. In subgroup analysis, EGFR-TKIs monotherapy provided more survival improvement for patients with exon 19 deletion than with L858R mutation (HR, 0.31 [0.13, 0.75] for exon 19 deletion, and 0.48 [0.35, 0.65] for L858R mutation, respectively).
Conclusions
These results showed that adjuvant EGFR-TKIs with or without chemotherapy can improve survival outcomes compared with placebo or adjuvant chemotherapy for resected EGFR-mutated NSCLC. Osimertinib provided the most DFS benefits and safety profile among the 6 treatments. Considering both efficacy and toxic effect, osimertinib is a promising agent in adjuvant setting for EGFR-mutant NSCLC, especially for those with exon 19 deletion.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Yi-Long Wu.
Funding
This project supported by the Guangdong Provincial Key Laboratory of Lung Cancer Translational Medicine (2017B0303141 20 to Y.L. WU), National Natural Science Foundation of China (81872510, 81673031 to W.Z. ZHONG).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
133P - Which patient subgroup needs more attention in early treatment failure? A matched cohort study of treatment failure patterns in locally advanced gastric cancer
Presenter: Dong Wu
Session: e-Poster Display Session
134P - Effect of preoperative tumour under-staging on the long-term survival of patients undergoing radical gastrectomy for gastric cancer
Presenter: Mi Lin
Session: e-Poster Display Session
135P - Significance of lymphatic invasion in the indication for additional gastrectomy after endoscopic treatment
Presenter: Hirohito Fujikawa
Session: e-Poster Display Session
136P - Modified ypTNM staging classification for gastric cancer after neoadjuvant therapy: A multi-institutional study
Presenter: Wen-Wu Qiu
Session: e-Poster Display Session
137P - Clinical utility of circulating tumour DNA (ctDNA) in resectable gastric cancer (GC)
Presenter: Mikhail Fedyanin
Session: e-Poster Display Session
138P - Prognostic importance of dynamic changes in systemic inflammatory markers for patients with gastric cancer
Presenter: Ying-Qi Huang
Session: e-Poster Display Session
139P - An intraoperative model for predicting survival and deciding therapeutic schedules: A comprehensive analysis of peritoneal metastasis in patients with advanced gastric cancer
Presenter: Zhi-Yu Liu
Session: e-Poster Display Session
140P - Preoperative and postoperative C-reactive protein levels predict recurrence and chemotherapy benefit in gastric cancer
Presenter: Li-Li Shen
Session: e-Poster Display Session
141P - Low expression of CDK5RAP3 and UFM1 indicates poor prognosis in patients with gastric cancer
Presenter: Ning-Zi Lian
Session: e-Poster Display Session
142P - Prognostic analysis of patients with intra-abdominal infectious complications after laparoscopy and open radical gastrectomy for gastric cancer: A propensity score-matching analysis
Presenter: Si-Jin Que
Session: e-Poster Display Session